

Dr M Karimi Shahri
Pathologist
16/8/2018

HBV and HCV

Serological and Molecular diagnoses

Introduction

- Principal viral diagnostic laboratory methods:
 - Culture
 - Antigen detection
 - Nucleic acid amplification test (NAAT)
 - Serology

Introduction

- NAAT
 - Highest sensitivity
 - Greater latitude in specimen collection, window for collections of specimen, and transport
 - Throughput time: One day or less

Introduction

- NAAT
 - Viral nucleic acid fragments may persist into recovery phase of illness (limiting their use as tests of cure)
 - Mutations in DNA or RNA target sequences can reduce sensitivity

Introduction

- **NAAT**
 - **PCR**
 - **Real time PCR**
 - **SDA** (standard displacement amplification)
 - **NASBA** (nucleic acid sequence based amplification)
 - **TMA** (transcription mediated amplification)
 - **LAMP**(loop mediated isothermal amplification)
 - **INAAT**(isothermal nucleic acid amplification technology)

Introduction

Nucleic Acid Amplified Test (NAAT)

<p>NAAT (PCR, Isothermal Amplification, SDA, LAMP)</p>	<ul style="list-style-type: none"> • Most sensitive • Define genotype sensitivities and prognosis • Moderate to very easy to perform • Low contamination risk if closed configuration used 	<ul style="list-style-type: none"> • May be more expensive than other options • Only detects pathogens defined by primers and probes • Limited multiplex options
<p>NAAT Panels</p>	<ul style="list-style-type: none"> • Comprehensive group of targets, not restricted to viruses • Highly sensitive • Same-day results 	<ul style="list-style-type: none"> • Expensive • Only detects pathogens defined by primers and probes • Does not differentiate between carrier vs. pathogenic viruses
<p>Next-Generation Sequencing</p>	<ul style="list-style-type: none"> • Emerging technique that can be used for viral detection and "de novo" characterization of unknown viruses • Assessment of antiviral susceptibility • Very high sensitivity compared to Sanger Sequencing • Exploration of viral outbreaks • Detection of viral variants 	<ul style="list-style-type: none"> • Very expensive • Not currently available to most clinical virology laboratories • Bioinformatics required
<p>Serology</p>		
<p>IgM</p>	<ul style="list-style-type: none"> • May be present during primary infections 	<ul style="list-style-type: none"> • Not useful for infections with short prodromal incubation times • Cross-reactivity with closely related viruses • Can also be detected during secondary infections
<p>IgG</p>	<ul style="list-style-type: none"> • Presence indicates immunity to certain viruses 	<ul style="list-style-type: none"> • Presence of viral-specific IgG does not always indicate immunity • Detection of rising IgG titers from acute and convalescent sera can take several weeks

Introduction

- Quantitative real time PCR
 - Standard of care in assessing viral loads and monitoring response to therapy

Introduction


- Viral Serology
 - Serum specimen are easy to obtain, transport and store
 - Two major clinical application:
 - Diagnosis of recent infection
 - Determination of immunity

Introduction

- Current/recent infection:
 - Virus specific IgM during the acute stage
 - Significant rise in virus specific IgG titre between acute and convalescent sera

Introduction

- General response patterns
 - Ig M appears in first week, disappears within 1 to 3 months
 - EIA methods are more sensitive
 - Ig G is produced 1-2 weeks following infection, peaks at 4-8 weeks and then declines...
 - Reactivation: IgM may reappear transiently, IgG rapidly increase in titre.




HBV

- Laboratory tests
 - assessment of liver disease
 - serologic markers of HBV replication
 - tests for coinfection with HCV, HDV, or HIV for those at risk.
 - The presence of **HBsAg** and **HBeAg** in addition to **HBV DNA viral load** quantitation are crucial components in the evaluation of patients with **chronic HBV infection** and in assessment of efficacy of anti viral treatment
 - Determination of the HBV genotype may be used to assess treatment efficacy and possible emergence of drug resistance


HDV?

- A defective RNA viroid that requires HBV surface antigen for full expression, replication, and transmission.
- HBV coinfection/superinfection with hepatitis D virus (HDV) is associated with a more severe course of hepatitis that frequently leads to rapid progressive fibrosis, hepatic decompensation, and the development of hepatocellular carcinoma.
- HDV is a blood-associated virus that may be transmitted from person to person in household situations in **endemic areas (Middle East, South America, Central Africa, Mediterranean countries)**.
- HDV is rare in the United States; needle sharing among intravenous drug abusers is the principal risk factor.
- Anti-HDV IgG and IgM testing is available when HDV coinfection is suspected in HBsAg-positive individuals

HBV



HBV



HBV

■ Serologic markers:

■ HBS Ag:

- A protein on the surface of hepatitis B virus;
- during acute or chronic hepatitis B virus infection
- the person is infectious
- The body normally produces antibodies to HBsAg as part of the normal immune response to infection.
- HBsAg is the antigen used to make hepatitis B vaccine.

HBV

Serologic markers:

- Anti-HBs:
 - recovery and immunity from hepatitis B virus infection.
 - Anti-HBs also develops in a person who has been successfully vaccinated against hepatitis B.

HBV



Serologic markers:

- Anti-HBc:
 - Appears at the onset of symptoms in acute hepatitis B and persists for life.
 - The presence of anti-HBc indicates previous or ongoing infection with hepatitis B virus in an undefined time frame.



HBV

- Serologic markers:
 - IgM anti-HBc:
 - Positivity indicates recent infection with hepatitis B virus (< 6 months).
 - Its presence indicates acute infection.

HBV



HBV



?

- HBS Ag Negative
- Anti HBc Negative
- Anti HBS Negative

- Susceptible

?

- HBS Ag Negative
- Anti HBc Positive
- Anti HBS Positive

- Immune due to natural infection

?

- HBS Ag Negative
- Anti HBc Negative
- Anti HBS Poistive

- Immune due to vaccination

?

- HBS Ag Positive
- Anti HBc Positive
- Ig M anti HBc Positive
- Anti HBS Negative

- Acutely infected

?

- HBS Ag Positive
- Anti HBc Positive
- Ig M anti HBc Negative
- Anti HBS Negative


- Chronically infected

?


- HBS Ag Negative
- Anti HBc Positive
- Anti HBS Negative

- 1. Resolved infection (most common)
- 2. False-positive anti-HBc, thus susceptible
- 3. "Low level" chronic infection
- 4. Resolving acute infection


HCV



HCV




HCV




HCV

- Available third-generation serology assays : high sensitivity and specificity
- POC tests can increase HCV screening opportunities.
- Presence of HCV-RNA reflects viral replication; sensitive molecular assays are used to diagnose active HCV infection in patients with a positive antibody test.
- The HCV-RNA can be detected before specific antibodies become detectable (within 1 to 3 weeks post exposure).
- The diagnosis of a chronic HCV infection: the presence of both HCV antibodies and HCV-RNA over a period of 6 months
- Quantitative HCV RNA tests are used to follow antiviral therapy in order to minimize side-effects, monitor emergence of resistance, and minimize costs.

HCV



HCV



HCV

- HCV genotyping is helpful for selecting appropriate treatment.

Serologic and Virologic Tests for Hepatitis Viruses

	IgM Anti-HAV	IgG Anti-HAV	HBsAg	Anti-HBs	IgM Anti-HBc	HBsAg	Anti-HBe	HBV DNA	Anti-HCV Screen	HCV RNA	Anti-HDV	Anti-HEV
HAV:												
Acute	+	+										
Remote	+	+										
HBV:												
Early			+	-	+	+	-	+				
Window			-	-	+	+	-	+				
Resolving			-/+	+	-	-/+	+	-/+				
Chronic			+	+/+	-	+	+/+	+				
TX monitoring:												
Remote			-	+	-	-/+	+/+	-/+				
HCV:												
Screen:												
Acute									+	+		
Chronic									+/+	+		
TX monitoring:												
Remote									+	+/+		
HDV:												
Superinfection			+	-	+/+	+	-/+	+/+			+	
HEV												
												+

Data from CDC: Surveillance for acute hepatitis, United States, 2007. MMWR 56(5-3), 2009.

HAV, hepatitis A virus; HDV, hepatitis D; HBsAg, hepatitis B surface antigen; HBe, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; IgM, immunoglobulin M; +, positive; -, negative.